Momenta Pharmaceuticals Commences Phase I Clinical Study for M118

Momenta Pharmaceuticals, Inc. has announced that it has initiated dosing for its Phase I study to evaluate the human safety and pharmacokinetics of M118, their lead novel development candidate M118 is a next-generation anticoagulant designed specifically for use in treating patients with Acute Coronary Syndromes (ACS).

M118 has been designed to combine the most attractive properties of different heparin products into one molecule.

Preclinical studies have shown that M118 could be a potent agent that provides consistent, flexible and reversible anticoagulant therapy, a future baseline anticoagulant therapy for ACS patients.

The clinical dosing of M118 highlights a major milestone for Momenta as it is the first novel therapeutic from the application of its technology to rational design and development of therapeutics.

Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals, Inc.


DownloadFull Press Release